Liste de contrôle

Pre-submission checklist: What's breaking first-cycle reviews — and how to get ahead of it

First-cycle review failure is no longer a rare setback — it's a pattern. With the FDA issuing more than 350 Complete Response Letters since 2025 and EMA negative opinions rising sharply, even scientifically rigorous programs are falling short. The reason is rarely weak data. It's the breakdown of the integrated narrative holding that data together.

Key highlights

The five failure patterns documented in this checklist repeat across programs and therapeutic areas with striking consistency — and they are largely visible in advance. Among the most common:

CMC uncertainty undermining strong clinical results — manufacturing questions can erode reviewer confidence even when efficacy and safety data are solid, particularly in cell and gene therapy programs
Label overreach and weak benefit-risk articulation — when commercial intent subtly outpaces the evidence base, or when clinical and safety sections tell subtly different stories, major review questions follow
Cross-functional misalignments that no single team is positioned to catch — the gaps between functions, not within them, are where experienced regulators look first

This checklist offers a practical framework for integrated submission readiness — one that spans strategic regulatory alignment, CMC and quality execution, clinical and evidence strategy, and market access planning. It is designed to help your team evaluate your program the way regulators will, so that the risks that derail first-cycle reviews are identified and addressed before they reach a reviewer.